Raffit Hassan Selected Research

amatuximab

1/2018	CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients.
12/2016	Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
4/2016	Population pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection.
2/2015	Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging.
12/2014	Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
11/2011	Effect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibody.
12/2010	Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers.
6/2010	Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy.
12/2007	Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Raffit Hassan Research Topics

Disease

87	Neoplasms (Cancer) 01/2022 - 11/2002
55	Mesothelioma 01/2022 - 11/2002
29	Malignant Mesothelioma 01/2022 - 06/2004
16	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 11/2002
8	Lung Neoplasms (Lung Cancer) 01/2022 - 03/2007
8	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022 - 05/2005
7	Disease Progression 01/2022 - 06/2010
7	Adenocarcinoma 01/2020 - 06/2004
7	Adenocarcinoma of Lung 01/2020 - 03/2007
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 03/2007
4	Thymoma (Thymic Carcinoma) 10/2019 - 11/2016
4	Carcinoma (Carcinomatosis) 04/2017 - 05/2007
4	Neoplasm Metastasis (Metastasis) 05/2015 - 08/2005
3	Hairy Cell Leukemia 10/2013 - 12/2006
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2022 - 01/2018
2	Pneumonia (Pneumonitis) 01/2022 - 02/2021
2	Capillary Leak Syndrome 11/2020 - 01/2013
2	Leukemia 06/2014 - 10/2007
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 03/2007 - 11/2002
2	Ovarian Epithelial Carcinoma 09/2005 - 05/2005
1	Arthrogryposis renal dysfunction cholestasis syndrome 01/2022
1	Renal Insufficiency (Renal Failure) 01/2022
1	Atrial Fibrillation 01/2022
1	Sepsis (Septicemia) 01/2022
1	Liver Failure 01/2022
1	Neutropenia 01/2022
1	Chills 02/2021
1	Fever (Fevers) 02/2021
1	Carcinogenesis 12/2020
1	Fatigue 01/2020
1	Diarrhea 01/2020
1	Vomiting 01/2020
1	Keratitis 01/2020

Drug/Important Bio-Agent (IBA)

64	MesothelinIBA 01/2022 - 11/2002
41	Immunotoxins (Immunotoxin)IBA 11/2020 - 11/2002
17	Monoclonal AntibodiesIBA 01/2018 - 05/2004
13	Proteins (Proteins, Gene)FDA Link 01/2020 - 05/2005
12	AntigensIBA 10/2019 - 10/2007
9	amatuximabIBA 01/2018 - 12/2007
8	Pemetrexed (MTA)FDA Link 01/2022 - 09/2011
8	AntibodiesIBA 10/2019 - 05/2005
7	Differentiation AntigensIBA 01/2020 - 06/2004
7	SS1(dsFv)PE38IBA 04/2016 - 11/2002
6	Biomarkers (Surrogate Marker)IBA 01/2022 - 04/2012
6	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 09/2011
6	Membrane Proteins (Integral Membrane Proteins)IBA 01/2020 - 08/2005
6	Membrane Glycoproteins (Membrane Glycoprotein)IBA 05/2015 - 11/2002
6	ExotoxinsIBA 11/2014 - 05/2004
5	Immune Checkpoint InhibitorsIBA 01/2022 - 12/2016
5	LMB-100IBA 11/2020 - 03/2017
5	Immunoconjugates (Immunoconjugate)IBA 01/2020 - 01/2011
5	Pharmaceutical PreparationsIBA 01/2020 - 10/2007
4	EpitopesIBA 01/2022 - 09/2005
4	PlatinumIBA 01/2022 - 01/2018
4	Surface Antigens (Surface Antigen)IBA 11/2020 - 01/2006
4	avelumabIBA 10/2019 - 11/2016
4	Bacterial ToxinsIBA 03/2016 - 02/2010
3	anetumab ravtansineIBA 01/2022 - 12/2016
3	AsbestosIBA 12/2020 - 01/2016
3	B7-H1 AntigenIBA 01/2020 - 01/2019
3	Pentostatin (Nipent)FDA LinkGeneric 06/2014 - 06/2011
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 06/2014 - 06/2011
3	VaccinesIBA 06/2014 - 02/2012
3	Paclitaxel (Taxol)FDA LinkGeneric 02/2010 - 08/2006
3	Tumor Biomarkers (Tumor Markers)IBA 07/2006 - 06/2004
3	Formaldehyde (Formol)FDA Link 12/2005 - 11/2002
3	ParaffinIBA 12/2005 - 11/2002
2	Bevacizumab (Avastin)FDA Link 01/2022 - 09/2011
2	olaparibIBA 10/2021 - 01/2020
2	NivolumabIBA 01/2021 - 01/2020
2	DNA (Deoxyribonucleic Acid)IBA 12/2020 - 01/2020
2	pembrolizumabIBA 11/2020 - 01/2020
2	130-nm albumin-bound paclitaxelIBA 01/2020 - 03/2017
2	LigandsIBA 01/2019 - 11/2016
2	Histone Deacetylase InhibitorsIBA 10/2017 - 09/2011
2	Neoplasm Antigens (Tumor Antigens)IBA 12/2016 - 05/2005
2	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 12/2015 - 06/2014
2	Immunoglobulin G (IgG)IBA 02/2015 - 05/2005
2	Immunoglobulin Variable RegionIBA 11/2014 - 12/2006
2	Antineoplastic Agents (Antineoplastics)IBA 06/2014 - 01/2006
2	Cancer VaccinesIBA 06/2014 - 03/2012
2	Neutralizing AntibodiesIBA 01/2013 - 06/2011
2	Messenger RNA (mRNA)IBA 11/2012 - 03/2007
2	Gemcitabine FDA Link 01/2012 - 12/2007
1	Vinorelbine (Navelbine)FDA LinkGeneric 01/2022
1	Chimeric Antigen ReceptorsIBA 01/2022
1	UbiquitinIBA 01/2021
1	IpilimumabIBA 01/2021
1	Interleukin-12 (IL 12)IBA 12/2020
1	Interleukin-3 (Interleukin 3)IBA 12/2020
1	Interleukin-10 (Interleukin 10)IBA 12/2020
1	CreatinineIBA 11/2020
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 11/2020
1	talazoparibIBA 01/2020
1	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 01/2020

Therapy/Procedure

44	Therapeutics 01/2022 - 11/2002
14	Immunotherapy 01/2022 - 08/2005
13	Drug Therapy (Chemotherapy) 01/2022 - 12/2007
2	Radiotherapy 01/2020 - 01/2018
1	Intravenous Administration 01/2022